AR011189A1 - 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion - Google Patents

1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion

Info

Publication number
AR011189A1
AR011189A1 ARP980101096A ARP980101096A AR011189A1 AR 011189 A1 AR011189 A1 AR 011189A1 AR P980101096 A ARP980101096 A AR P980101096A AR P980101096 A ARP980101096 A AR P980101096A AR 011189 A1 AR011189 A1 AR 011189A1
Authority
AR
Argentina
Prior art keywords
compounds
hydrogen
6alkyl
preparation
alkyl
Prior art date
Application number
ARP980101096A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR011189A1 publication Critical patent/AR011189A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/007Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1,4-benzotiazepin-1,1-dioxidos que comprende la formula (I), en la que R1 es un grupo alquilo de C1-6 de cadena lineal; R2 es un grupo alquilo deC1-6 de cadena lineal; R3 es hidrogeno o un grupo OR11 en el que R11 es hidrogeno, un grupoalquilo de C1-6 o alquilcarbonilo de C1-6 opcionalmentesustituidos; R4 es piridilo o fenilo opcionalmente sustituido; R5, R6 y R8 son iguales o diferentes y cada uno se selecciona de hidrogeno, halogeno, ciano,R15-acetiluro, OR15, alquilo de C1-6op cionalmente sustituido, COR15, CH(OH)R15, S(O)nR15, P(O)(OR15)2, OCOR15, OCF3, OCN, SCN, NHCN, CH2OR15, CHO,(CH2)pCN, CONR12R13, (CH2)pCO2R15, (CH2)pNR12R13, CO2R15, NHCOCF3, NHSO2R15, OCH2OR15, OCH=CHR15, O(CH2CH2O)nR15,O(CH2)pSO3R15, O(CH2)pNR12R13 yO(CH2)pN+R12R14 en los que p es un numero entero de 1-4; n es un numero entero de 0-3 y R12, R13, R14 y R15 se seleccionan independientemente de hidrogeno yalquilo de C1-6 opcionalmente sustituido; R7 es un grupo dela formula (II) en la que los grupos hidroxilo pueden estar sustituidos con acetilo o bencilo,o formula:-alquil(C1-C6)-R17 en el que el grupo alquilo puede estar sustituido con uno o más grupos hidroxilo; R16 es -COOH o -CH2-OH; R17 es H, -OH,-NH2,-COOH o COOR1 8; R18 es alquilo (C1-C4) o -NH-alquilo (C1-C4); X es -NH- u -O-; y R9 y R10 son iguales o diferentes y cada uno es hidrogeno o alquilo de C1-6;y sus sales, solvatos y derivados fisiologicamente funcionales; a composicionesfarmacéuticas que los con tienen y a su uso en medicina, particularmente en laprofilaxis y tratamiento de estados hiperlipemiantes, tal como la ateroesclorosis, a sus procedimientos para su preparacion y nuevos compuestosintermediariospara su preparacion.
ARP980101096A 1997-03-14 1998-03-11 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion AR011189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97104348 1997-03-14

Publications (1)

Publication Number Publication Date
AR011189A1 true AR011189A1 (es) 2000-08-02

Family

ID=8226598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101096A AR011189A1 (es) 1997-03-14 1998-03-11 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion

Country Status (23)

Country Link
US (2) US6020330A (es)
EP (1) EP0864582B1 (es)
JP (1) JP3282998B2 (es)
KR (1) KR19980080223A (es)
CN (1) CN1070484C (es)
AR (1) AR011189A1 (es)
AT (1) ATE242258T1 (es)
AU (1) AU731575B2 (es)
BR (1) BR9801126A (es)
CA (1) CA2231971C (es)
CZ (1) CZ75998A3 (es)
DE (1) DE69815180T2 (es)
DK (1) DK0864582T3 (es)
ES (1) ES2198613T3 (es)
HU (1) HUP9800541A3 (es)
ID (1) ID20053A (es)
IL (1) IL123648A (es)
NZ (1) NZ329932A (es)
PL (1) PL325363A1 (es)
PT (1) PT864582E (es)
RU (1) RU2179977C2 (es)
TR (1) TR199800444A2 (es)
ZA (1) ZA982140B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
PT864582E (pt) * 1997-03-14 2003-10-31 Aventis Pharma Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー.ディー.サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
US6569905B1 (en) 1998-12-23 2003-05-27 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
WO2000038721A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
EA009466B1 (ru) 1998-12-23 2007-12-28 Джи.Ди. Сирл Ллс Ингибитор белка, переносящего эфир холестерила
DE69907960T2 (de) 1998-12-23 2004-02-26 G.D. Searle Llc, Chicago Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CN1930137B (zh) 2004-02-27 2011-07-20 旭化成制药株式会社 苯并硫氮杂卓和苯并虑平化合物
DE102005033099A1 (de) * 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
US9339480B2 (en) * 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX345040B (es) 2010-11-08 2017-01-16 Albireo Ab Una combinacion farmaceutica que comprende un inhibidor de ibat y un aglutinante de acido biliar.
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CA2977588C (en) * 2015-03-02 2023-10-03 Apeiron Biologics Ag Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
FI3921028T3 (fi) 2019-02-06 2023-01-31 Bentsotiadiatsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504645A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
AU2023255249A1 (en) 2022-04-22 2024-10-17 Albireo Ab Subcutaneous administration of an asbt inhibitor
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240173333A1 (en) 2022-11-03 2024-05-30 Albireo Ab Treating Alagille Syndrome (ALGS)
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
HUT71819A (en) * 1992-11-09 1996-02-28 Boots Co Plc 1,4-benzothiazepine derivatives and pharmaceutical compositions containing them
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
PT864582E (pt) * 1997-03-14 2003-10-31 Aventis Pharma Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos

Also Published As

Publication number Publication date
ID20053A (id) 1998-09-17
DK0864582T3 (da) 2003-09-29
AU731575B2 (en) 2001-04-05
CA2231971A1 (en) 1998-09-14
ZA982140B (en) 1998-09-14
HU9800541D0 (en) 1998-05-28
EP0864582B1 (en) 2003-06-04
CN1194979A (zh) 1998-10-07
EP0864582A3 (en) 1998-10-21
RU2179977C2 (ru) 2002-02-27
HUP9800541A1 (hu) 1999-06-28
US6020330A (en) 2000-02-01
BR9801126A (pt) 2000-03-21
CN1070484C (zh) 2001-09-05
IL123648A0 (en) 1998-10-30
AU5834998A (en) 1998-09-17
ATE242258T1 (de) 2003-06-15
PT864582E (pt) 2003-10-31
IL123648A (en) 2000-11-21
HUP9800541A3 (en) 2000-08-28
PL325363A1 (en) 1998-09-28
US6114322A (en) 2000-09-05
JPH10279568A (ja) 1998-10-20
NZ329932A (en) 1999-01-28
TR199800444A3 (tr) 1998-10-21
ES2198613T3 (es) 2004-02-01
DE69815180D1 (de) 2003-07-10
DE69815180T2 (de) 2004-04-29
CA2231971C (en) 2008-05-20
EP0864582A2 (en) 1998-09-16
CZ75998A3 (cs) 1998-09-16
TR199800444A2 (xx) 1998-10-21
KR19980080223A (ko) 1998-11-25
JP3282998B2 (ja) 2002-05-20

Similar Documents

Publication Publication Date Title
AR011189A1 (es) 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
AR018169A1 (es) Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret
AR037247A1 (es) Compuestos inhibidores de dipeptidil peptidasa iv (dp-iv), sus composiciones farmaceuticas y usos, y metodos de tratamiento de enfermedades de humanos tales como tolerancia alterada a la glucosa, diabetes tipo 2 e hiperglucemia
AR037504A1 (es) Derivados de 1,6-naftiridina, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la diabetes y trastornos relacionados
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
AR033594A1 (es) Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
AR047008A1 (es) Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos.
AR048717A1 (es) Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
MX9307654A (es) Derivados de amina, proceso para su preparacion y composicion farmaceutica que los contiene.
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
ATE356624T1 (de) Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
ES2119326T3 (es) Compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
IS5401A (is) Samsetning mónóamínoxídasa hemils og h5-HT1B mótlyfs eða gerandefnis með hlutaverkun
CO4810374A1 (es) Nueva utilizacion de compuestos para actividad anti- pruritica
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
DK118083D0 (da) Theophyllinylalkyloxadiazoler eller additionssalte deraf, deres fremstilling og anvendelse som laegemidler
ES2116467T3 (es) Derivados de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona, su preparacion y los medicamentos que les contienen.
DK0379412T3 (da) Derivater af 1,8-benzonaphthyridin, fremstilling af disse forbindelser og midler, som indeholder forbindelserne
ES2133686T3 (es) Nuevos derivados de benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.